Asia
Kangmei will supply the JV with 95% of the $7.6M in cash, while BGI will contribute the remaining 5% of the JV’s value with instruments and technology.
The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
It seems those thousands of anticipated and dreaded pink slips at Teva will be handed out on Thursday.
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Esaote S.p.A., an Italian medical imaging company, has been acquired by a group of China investors.
Teva may be passing out more pink slips as the company looks to cut up to 10,000 jobs in order to save up to $2B in costs over the next two years.
Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility.
With the latest funding, Genova has raised $200M in capital.
PRESS RELEASES